The first real-world analysis of the Pfizer coronavirus vaccine suggests it is matching its performance in clinical trials, but raises serious questions about the UK’s decision to delay the second dose.
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.